Bristol-Myers Squibb-Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Company Performance - Bristol Myers Squibb (BMY) closed at $60.28, reflecting a +0.79% change from the previous trading day's close, outperforming the S&P 500's daily loss of 0.91% [1] - The stock has gained 6.52% over the past month, while the Medical sector lost 1.88% and the S&P 500 lost 7.38% during the same period [1] Earnings Expectations - Analysts expect Bristol Myers Squibb to report earnings of$ 1.55 per share, indicating a year-over-year growth of 135.23% [2] - The Zacks Consensus Estimate for revenue is projected at $10.69 billion, down 9.94% from the previous year [2] - For the full year, earnings are projected at$ 6.75 per share, showing a growth of +486.96%, while revenue is expected to be $45.59 billion, reflecting a decrease of -5.6% from the prior year [3] Analyst Estimates and Rankings - Recent modifications to analyst estimates indicate changing business trends, with positive changes suggesting a favorable outlook on the company's health and profitability [4] - The Zacks Rank system, which evaluates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold) [6] Valuation Metrics - Bristol Myers Squibb has a Forward P/E ratio of 8.86, which is a discount compared to the industry average Forward P/E of 18.77 [7] - The company has a PEG ratio of 2.22, compared to the industry average PEG ratio of 1.51 [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries [9]